ReviewExperimental & molecular medicine2023
Primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD): a condition exemplifying the crosstalk of the gut-liver axis.
Review in Experimental & molecular medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.
- Bibliometric analysis of research on gut microbiota and bile acids: publication trends and research frontiers.Frontiers in microbiology · 2024Pooled it
- Gut microbiota in health and disease.Molecular biomedicine · 2026Review
- Epidemiology of primary sclerosing cholangitis in general and IBD populations: a systematic review and meta-analysis.Hepatology international · 2026Article
- Rescue Vedolizumab Therapy for a Rare Case of Complicated Severe Ulcerative Colitis: A Case Report and Literature Review.Journal of clinical medicine · 2026Article
- Article
- Molecular and mechanistic insights into the gut-liver axis inInfection and immunity · 2026Review
- Functional changes in the gut microbiota are associated with the intestinal phenotype in A20 haploinsufficiency.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2026Article
- Gut Microbiota and Interorgan Communication Among the Gut, Brain, and Beyond.Internal medicine (Tokyo, Japan) · 2026Review
- Genetic architecture of primary sclerosing cholangitis: shared pathways with inflammatory bowel disease and gut-liver axis mediation.International journal of surgery (London, England) · 2026Article
- Systemic PCSK9 elevation characterises autoimmune liver disease across sexes.Scientific reports · 2025Article
- Impact of Metabolic Dysfunction-Associated Steatotic Liver Disease on Fatigue and Pruritus in Primary Sclerosing Cholangitis: A U.S. Single-Center Study.Journal of clinical medicine · 2025Article
- Article
- Haplotype analysis reveals pleiotropic disease associations in the HLA region.American journal of human genetics · 2025Article
- Phenotypic Differences and Clinical Outcomes of South Asian Children With IBD: A Singapore-Malaysia Study From the Asian PIBD Registry Network.Journal of gastroenterology and hepatology · 2025Article
- Strain-specific responses to dextran sulfate sodium-induced ulcerative colitis in BALB/c and C57BL/6 mice: Comparative analysis of local versus extra-intestinal manifestations.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025Article
- Navigating Neoplasm Risk in Inflammatory Bowel Disease and Primary Sclerosing Cholangitis.Cancers · 2025Review
- Hepatic Nuclear Receptors in Cholestasis-to-Cholangiocarcinoma Pathology.The American journal of pathology · 2025Review
- A Closer Look into Autoimmune Liver Diseases.International journal of molecular sciences · 2025Review
- Unveiling the gut-liver axis: the behind-the-scenes "manipulator" of human immune function.Frontiers in immunology · 2025Review
- The role of brain-liver-gut Axis in neurological disorders.Burns & trauma · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
The close relationship between primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD) provides a good opportunity to comprehend the gut-liver axis. The gut and the liver have reciprocal interactions, including how gut inflammation influences the liver through immune cells and the microbiota and how the microbiota in the gut modifies bile acids, which are produced and secreted from the liver. PSC-IBD shows distinct clinical findings from classical IBD. In addition, a distinct genetic predisposition and unique microbiota composition suggest that PSC-IBD is an independent disease entity. Understanding the pathogenesis of PSC-IBD helps to develop novel and effective therapeutic agents. Given the high risk of malignancies associated with PSC-IBD, it is critical to identify patients at high risk and implement appropriate surveillance and monitoring strategies. In this review, we provide an overview of PSC-IBD, which exemplifies the gut-liver axis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.